|
Abnormal behavior
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
VGF knockout mice display behavioral abnormalities such as higher depressive behavior and memory dysfunction.
|
28680036 |
2017 |
|
Abnormal behavior
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Author Correction: Behavioral abnormalities with disruption of brain structure in mice overexpressing VGF.
|
30455452 |
2018 |
|
Abnormal behavior
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, the behavioral changes in responses to various doses may be related to the upregulation (0.025 and 0.05 mg/kg) and downregulation (1 and 3 mg/kg) of brain-derived neurotrophic factor and VGF in the hippocampus and prefrontal cortex in mice.
|
29020410 |
2018 |
|
Abnormal behavior
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
However, the role of VGF in human psychiatric disorders is unknown.
|
20631166 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, our findings show how VGF can confer TKI resistance and trigger EMT, suggesting its potential utility as a biomarker and therapeutic target in lung adenocarcinoma.<i></i>.
|
28381546 |
2017 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
VGF serves a dual role in the glioblastoma hierarchy by promoting GSC survival and stemness in vitro and in vivo while also supporting DGC survival and inducing DGC secretion of BDNF.
|
29625067 |
2018 |
|
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Here, we extended the study of VGF by comparing levels in cerebrospinal fluid (CSF) from 44 DLB patients, 20 Alzheimer's disease (AD) patients, and 22 cognitively normal controls selected from the Amsterdam Dementia Cohort.
|
31547145 |
2019 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Future work will be needed to determine the specificity of VGF for AD versus other neurodegenerative diseases.
|
31305322 |
2020 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
In contrast, neurosecretory protein VGF was lower in patients with AD than in patients with MCI (ß = -0.93 [SE 0.22]) and control subjects (ß = 0.46 [SE 0.19]).
|
29370833 |
2018 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Secretogranin-2 (p<0.005) and neurosecretory protein VGF (p<0.001) concentrations were lowered in AD.
|
29028155 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
VGF is decreased throughout ALS (<i>p</i> < 0.05).
|
30618638 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Taken together, selective VGF fragment depletion may participate in disease onset and/or progression of ALS.
|
27737014 |
2016 |
|
Amyotrophic Lateral Sclerosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Previous proteomic evidence revealed that the content of certain peptide fragments including Vgf-derived peptide aa 398-411 (Vgf(398-411)) of the precursor Vgf protein in the cerebral spinal fluid (CSF) correctly identified patients with ALS from normal and disease controls.
|
18432310 |
2008 |
|
Amyotrophic Lateral Sclerosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings suggested that VGF was involved in the pathology of ALS.
|
30656593 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.060 |
Biomarker
|
disease |
LHGDN |
Identification of potential CSF biomarkers in ALS.
|
16481598 |
2006 |
|
Amyotrophic Lateral Sclerosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
These data suggest that VGF plays a critical role in motor neuron survival and may be a potential new therapeutic target for ALS, and SUN N8075 may become a potential therapeutic candidate for treatment of ALS.
|
21151573 |
2010 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Changes in expression levels of VGF, as well as of two additional proteins previously reported to be overexpressed in PNI, Nestin and Neuromodulin (GAP43), closely recapitulated our proteomic findings in PDAC tissues.
|
30690892 |
2019 |
|
Behavioral Symptoms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our findings indicate that long-term post-weaning social isolation alters signaling via VGF/BDNF/TrkB and nNOS that could interfere with neurodevelopmental processes which may contribute to pathological behavioral symptoms in adulthood.
|
31128132 |
2019 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
A neuropeptide precursor VGF has potent antidepressant effects and has been reportedly associated with bipolar disorder.
|
24934694 |
2014 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
The dysregulation of VGF in bipolar disorder as well as the behavioral effects of the neuropeptide similar to LiCl suggests that VGF may underlie the pathophysiology of bipolar disorder.
|
20631166 |
2010 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
The dysregulation of VGF in bipolar disorder as well as the behavioral effects of the neuropeptide similar to LiCl suggests that VGF may underlie the pathophysiology of bipolar disorder.
|
20631166 |
2010 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of VGF in bladder cancer cell lines inhibited cell growth.
|
24830820 |
2014 |
|
Breast Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
We isolated plasma DNA from 340 participants in a breast cancer case control project to study promoter methylation levels of five genes previously shown to be associated with breast cancer in frozen tissue and in cell line DNA: MAL, KIF1A, FKBP4, VGF and OGDHL.
|
24927296 |
2014 |
|
Carcinoma of bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of VGF in bladder cancer cell lines inhibited cell growth.
|
24830820 |
2014 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition.
|
28381546 |
2017 |